Hypereosinophilic Syndrome - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hypereosinophilic Syndrome - Pipeline Review, H1 2016', provides an overview of the Hypereosinophilic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypereosinophilic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypereosinophilic Syndrome and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome - The report reviews pipeline therapeutics for Hypereosinophilic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hypereosinophilic Syndrome therapeutics and enlists all their major and minor projects - The report assesses Hypereosinophilic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hypereosinophilic Syndrome - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hypereosinophilic Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hypereosinophilic Syndrome Overview 6 Therapeutics Development 7 Pipeline Products for Hypereosinophilic Syndrome - Overview 7 Hypereosinophilic Syndrome - Therapeutics under Development by Companies 8 Hypereosinophilic Syndrome - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Hypereosinophilic Syndrome - Products under Development by Companies 11 Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development 12 Bristol-Myers Squibb Company 12 GlaxoSmithKline Plc 13 Knopp Biosciences LLC 14 Kyowa Hakko Kirin Co., Ltd. 15 Stemline Therapeutics, Inc. 16 Hypereosinophilic Syndrome - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 benralizumab - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 dasatinib - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 dexpramipexole dihydrochloride - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 mepolizumab - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 SL-401 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Hypereosinophilic Syndrome - Recent Pipeline Updates 39 Hypereosinophilic Syndrome - Dormant Projects 51 Hypereosinophilic Syndrome - Product Development Milestones 52 Featured News & Press Releases 52 Mar 13, 2014: Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole 52 Jan 08, 2014: Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development for Hypereosinophilic Syndrome, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Hypereosinophilic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2016 12 Hypereosinophilic Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2016 13 Hypereosinophilic Syndrome - Pipeline by Knopp Biosciences LLC, H1 2016 14 Hypereosinophilic Syndrome - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 15 Hypereosinophilic Syndrome - Pipeline by Stemline Therapeutics, Inc., H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 25 Hypereosinophilic Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 39 Hypereosinophilic Syndrome - Dormant Projects, H1 2016 51
List of Figures
Number of Products under Development for Hypereosinophilic Syndrome, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Top 10 Targets, H1 2016 18 Number of Products by Stage and Top 10 Targets, H1 2016 18 Number of Products by Top 10 Mechanism of Actions, H1 2016 20 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 20 Number of Products by Routes of Administration, H1 2016 22 Number of Products by Stage and Routes of Administration, H1 2016 22 Number of Products by Molecule Types, H1 2016 24 Number of Products by Stage and Molecule Types, H1 2016 24
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.